**Unlocking Epigenetic Secrets from the Uterus:**

**Therapeutic Options for Advanced and Recurrent Endometrial Cancer – Tweetorial #2**

**References**

**Tweet 2:**

Makker V. Breaking new ground in the treatment of advanced endometrial cancer. *Oncology.* 2019;19:239-242.

The Cancer Genome Atlas Research Network (TCGA). Integrated genomic characterization of endometrial carcinoma. *Nature.* 2013;497:67-73.

**Tweet 3:**

Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). *J Clin Oncol.* 2020;38:3841-3850.

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Uterine Neoplasms. Version 1.2021—October 20, 2020. Accessed December 2, 2020.

https://www.nccn.org/professionals/physician\_gls/pdf/uterine.pdf

**Tweet 4:**

Humber CE, Tierney JF, Symonds RP, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. *Ann Oncol.* 2007;18:409-420.

Sorbe B, Andersson H, Boman K, Rosenberg P, Kalling M. Treatment of primary and advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel—long-term follow-up. *Int J Gynecol Cancer.* 2008;18:803-808.

**Tweet 5:**

van Weelden WJ, Massuger LFAG, Pijenborg JMA, Romano A. Anti-estrogen treatment in endometrial cancer: a systematic review. *Front Oncol.* 2019;9:359.

**Tweet 7:**

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Uterine Neoplasms. Version 1.2021—October 20, 2020. Accessed December 2, 2020. https://www.nccn.org/professionals/physician\_gls/pdf/uterine.pdf

**Tweet 8:**

Soliman PT, Westin SN, Iglesias DA, et al. Everolimus, letrazole, and metformin in women with advanced or recurrent endometroid cancer: a multi-center, single-arm, phase II study. *Clin Cancer Res.* 2020;26:581-587.

**Tweet 9:**

Erickson BK, Zeybek B, Santin AD, Fader AN. Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies. *Curr Opin Obstet Gynecol.* 2020;32:57-64.

**Tweet 11:**

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Uterine Neoplasms. Version 1.2021—October 20, 2020. Accessed December 2, 2020.

https://www.nccn.org/professionals/physician\_gls/pdf/uterine.pdf

**Tweet 12:**

Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (Stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu (NCT01367002): updated overall survival analysis. *Clin Cancer Res*. 2020;26:3928-3935.

**Glossary**

AEs, adverse effects/events

AI, aromatase inhibitor

carb, carboplatin

cis, cisplatin

CR, complete response

dMMR, mismatch repair deficient

DOR, duration of response

dox, doxorubicin

EC, endometrial cancer

EGFR, epidermal growth factor receptor

ERK, extracellular signal-regulated kinases

GI, gastrointestinal

GOG 209, Gynecologic Oncology Group 209 trial

HER2, human epidermal growth factor receptor 2

HT, hormone therapy

MEK, mitogen-activated protein kinase

meta tox, metabolic toxicities

mOS, median overall survival

mPFS, median progression-free survival

MSI-H, microsatellite instability high

mTOR, mechanistic target of rapamycin kinase

NCCN, National Comprehensive Cancer Network

ORR, objective or overall response rate

OS, overall survival

pac, paclitaxel

PFS, progression-free survival

Ph2/Ph3, phase 2 and phase 3

PI3K, phosphoinositide-3-kinase

PN, peripheral neuropathy

PR, partial response

Pt, patient

PTEN, phosphatase and tensin homolog

SD, stable disease

SERD, selective estrogen down-regulator

SERM, selective receptor modulator

TAP, paclitaxel/doxorubicin/cisplatin

TCGA, The Cancer Atlas Program

tras, trastuzumab

TTP, thrombocytopenia

USC, uterine serous carcinoma

w/, with